oleanolic acid-3-O-{α-L-rhamnopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-α-L-arabinopyranoside} 28-O-[β-D-glucopyranosyl] ester | 211815-98-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: oleanolic acid-3-O-{α-L-rhamnopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-α-L-arabinopyranoside} 28-O-[β-D-glucopyranosyl] ester
• 英文别名: β-D-glucopyranosyl 3-[(O-β-D-glucopyranosyl-(1->3)-O-[α-L-rhamnopyranosyl-(1->2)]-α-L-arabinopyranosyl)oxy]olean-12-en-28-oate；3-O-β-D-glucopyranosyl(1->3)-[α-L-rhamnopyranosyl(1->2)]-α-L-arabinopyranosyl oleanolic acid 28-O-β-D-glucopyranosyl ester；ilekudinoside A；nudicaucin C；guaianin O；[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-5-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
• CAS: 211815-98-4
• 化学式: C₅₃H₈₆O₂₁
• 分子量: 1059.25
• InChiKey: ULSOTXJNUTYKRK-DFRCHCFDSA-N

物化性质

• 熔点：
  360-365 °C (decomp)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  74
• 可旋转键数：
  11
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  334
• 氢给体数：
  12
• 氢受体数：
  21

反应信息

• 作为反应物：
  描述：

  oleanolic acid-3-O-{α-L-rhamnopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-α-L-arabinopyranoside} 28-O-[β-D-glucopyranosyl] ester 在 水 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 葡萄糖 、 3β-[(O-β-D-glucopyranosyl-(1->3)-O-[α-L-rhamnopyranosyl-(1->2)]-α-L-arabinopyranosyl)oxy]olean-12-en-28-oic acid
  参考文献：
  名称：

  番石榴花中新皂苷的分离鉴定

  摘要：

  三萜皂苷，愈创木酚O（1），齐墩果酸3- O- {α- L-鼠李吡喃糖基- （1→2）-[β- D-吡喃吡喃糖基- （1→3）]-α- L-阿拉伯吡喃糖苷}-从菊苣花的正丁醇提取物中分离出28- O- [β- D-吡喃葡萄糖基]-酯。通过对一维和二维1 H，13 C的大量研究，完成了1的结构解析。-NMR光谱，FAB质谱以及碱和酸水解。

  DOI：

  10.1080/14786410902884693

文献信息

• Methods and compositions for treatment of COPD diseases
  申请人：Shanghai KE Pharmaceutical Co., LTD

  公开号：US10786521B2

  公开（公告）日：2020-09-29

  The present disclosure relates to treatment of a pulmonary disease. The methods and kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc.).

  本公开涉及肺部疾病的治疗。本文提供的方法和试剂盒有助于缓解肺部疾病（如哮喘、慢性阻塞性肺病（COPD）等）引起的症状。
• EXTRACTION METHOD, TOTAL SAPONIN AND USE OF ILEX KUDINGCHA C.J.TSENG LEAVES
  申请人：Peking University

  公开号：EP2668954B1

  公开（公告）日：2016-03-02
• METHODS AND COMPOSITIONS FOR TREATMENT OF COPD DISEASES
  申请人：Shanghai KE Pharmaceutical Co., Ltd

  公开号：EP3131556A1

  公开（公告）日：2017-02-22
• KUDINOSIDES FOR USE IN THE TREATMENT OF COPD DISEASES
  申请人：Shanghai KE Pharmaceutical Co., Ltd

  公开号：EP3131556B1

  公开（公告）日：2019-10-09
• EXTRACTION METHOD FOR ILEX KUDINGCHA C. J. TSENG LEAVES, TOTAL SAPONINS AND USE THEREOF
  申请人：Tu Pengfei

  公开号：US20130303469A1

  公开（公告）日：2013-11-14

  The present invention provides an extraction method for the leaves of Ilex kudingcha C. J. Tseng, and the total saponins from I. kudingcha leaves extracted by using this method, and use of the total saponins in preparing a drug for reducing cholesterol and blood lipids and anti-atherosclerosis. The extraction method comprises the following steps: subjecting I. kudingcha leaves to refluxing extraction with ethanol aqueous solution to obtain an extracted solution; filtering the extracted solution and removing ethanol, and then separating and purifying the solution using a macroporous resin column.